FDA Drug Approvals for Cancer in 2016

Slideshow

This slide show highlights 2016 FDA approvals of cancer treatments, which to date include therapies for RCC, neuroendocrine tumors, Hodgkin lymphoma, CLL, sarcoma, bladder cancer, lung cancer, and breast cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
6371178759112
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
Related Content
Investigators will assess the safety, pharmacology, and maximum tolerated dose of ST-001 in relapsed/refractory SCLC as part of a phase 1a/1b trial.

FDA Accepts IND Application for ST-001 in Relapsed/Refractory SCLC

Russ Conroy
April 9th 2025
Article

Investigators will assess the safety, pharmacology, and maximum tolerated dose of ST-001 in relapsed/refractory SCLC as part of a phase 1a/1b trial.

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Sarah Sammons;Rachel A. Freedman;Adam M. Brufsky;Ahmad Awada;Sara A. Hurvitz, MD;Nancy U. Lin, MD;Cristina Saura;Sheri Leung;Bethann S Hromatka
April 9th 2025
Podcast
Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC

Roman Fabbricatore
April 9th 2025
Article

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Promoting Psychosocial Cancer Care on World Psycho-Oncology Day

Promoting Psychosocial Cancer Care on World Psycho-Oncology Day

Tim Cortese
April 9th 2025
Article

The International Psycho-Oncology Society announced the first ever WPOD on April 9, 2025, to bring more focus to psychosocial care in cancer therapy.

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

Caroline Welsh;Nicole Taylor;Julie Cole;Manjeet Chadha
April 8th 2025
Article